A Study on the Efficacy of Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Leaf Extract in Adults With Osteoarthritis of the Knee.

Inclusion Criteria: * Male or female 45-70 years of age * Body mass index (BMI) 18.0-39.9 kg/m2 * If female, subject is not of child bearing potential OR female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. * Primary or secondary, unilateral or bilateral osteoarthritis of the knee (American College of Rheumatology Clinical Criteria for Classification) characterized as knee pain with at least 3 of the following: * Age \> 50 years * Stiffness \< 30 minutes * Crepitus * Bony Tenderness * Bony enlargement * No palpable warmth * Self reported difficulty performing at least one of the following activities because of knee pain: * lifting and carrying groceries * walking one-quarter of a mile * getting in and out of a chair * going up and down stairs * mobility * self-care activities * Able to walk unassisted (may use walking stick, crutch, or knee brace) * Availability for duration of the study period (2 week run-in +12 weeks) * Subject agrees not to use over-the-counter medications or natural health products intended to treat OA pain during the run-in period and throughout the study (except the rescue medication provided). * Subject using other therapies for OA, such as exercise, heat/cold therapy, joint protection and physiotherapy/occupational therapy agrees to continue these therapies as normal avoiding changes in frequency or intensity and to record therapies in the study diary * Subject agrees not to start any new therapies for OA during the course of the study * Agrees to maintain current exercise and dietary habits for the duration of the study * Has given voluntary, written, informed consent to participate in the study Exclusion Criteria: * Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial * Physical examination findings show severe articular inflammation * Subject has a diagnosis of rheumatoid arthritis, fibromyalgia, spinal disorders or other musculoskeletal disease * Subject has been recommended for knee surgery * WOMAC Pain Scale Score \<4 for total pain (average of question #1 to question #5) at screening and baseline * Subject has kidney or liver disease, blood disorders, active cancer and/or HIV infection * Subjects with significant medical history or current metabolic disorders, thyroid disease, immune disorders and/or cardiovascular disease will be reviewed by the Qualified Investigator (QI). Subjects deemed by the QI to be at possible risk will not be permitted in this study. * Subjects with a Type I or II diabetes * Subjects with a history of seizures who are currently on medication to control seizures * Subjects with hypertension will be reviewed by the Qualified Investigator (QI). If the subject is considered to be at risk they will not be permitted in this study * Subjects with a history of reoccurring palpitations or dizziness * Use of illicit drugs or history of drug or alcohol abuse with the past 2 years (currently having more than 2 standard alcoholic drinks per day) * Planned surgery during the course of the trial * Use of intra-articular, oral or parenteral corticosteroids, or other injectable prescription medication (e.g., Synvisc) within 2 months prior to randomization and during the trial * Subjects taking prescription medication that affect blood coagulation (e.g. blood thinners, clotting factor replacements, acetylsalicylic acid) * Subjects regularly taking over-the-counter medication (e.g. acetylsalicylic acid, ibuprofen) or natural health products (i.e. fish oils, vitamin E) that affect blood coagulation within 2 weeks of randomization * Requires the use of prescription drugs to control pain (other than provided rescue medication) * Use of oral or topical prescription or over the counter medications or natural health products for pain relief during the run-in period and during the trial (other than provided rescue medication, rescue medication should not be used within 72 hours prior to baseline and subsequent visits) * Use of vitamins and minerals or natural health products/dietary supplements indicated for arthritis such as glucosamine and chondroitin sulfate within 2 weeks prior to the run-in period and during the trial * Clinically significant abnormal laboratory results at screening (i.e. ≥ 2 times the ULN) * Allergy or sensitivity to test product ingredients, including shellfish * Allergy or sensitivity to acetaminophen, the rescue medication * Individuals who are cognitively impaired and/or who are unable to give informed consent * Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject